MedPath

A study to compare effectiveness for preventing disease recurrence and safety regarding drug related side effects between one month vs. two month of alternate day oral steroid in children with nephrotic syndrome, a chronic protein losing kidney disease.

Phase 3
Recruiting
Conditions
Health Condition 1: null- Nephrotic Syndrome
Registration Number
CTRI/2015/01/005363
Lead Sponsor
RS Medical College and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

Infrequent relapse nephrotic syndrome; No previously intake of any steroid sparing agent; Informed written consent.

Exclusion Criteria

Patients with severe leucopenia (leucocytes <3•0Ã? 1000 cells/mm3), severe anemia (haemoglobin <8•9 g/dl), severe thrombocytopenia (platelet <100•0 Ã? 1000 cells/mm3), deranged liver function tests (AST or ALT to >50 IU/L), or any active infection

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sustained remission at 12 monthsTimepoint: 3,6,9 and 12 month
Secondary Outcome Measures
NameTimeMethod
number of relapses, cumulative steroid doseTimepoint: 3,6,9 and 12 month
© Copyright 2025. All Rights Reserved by MedPath